Perrault J, Greseth J L, Tremaine W J
Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905.
Mayo Clin Proc. 1991 May;66(5):480-4. doi: 10.1016/s0025-6196(12)62388-x.
Nineteen patients (12 children and 7 adults) with severe Crohn's disease, all of whom were dependent on corticosteroids, were treated with 6-mercaptopurine. All patients received a daily dose of 6-mercaptopurine of 50 mg; in two pediatric patients with a poor response after 2 months, the dosage was increased to 75 mg/day. A complete or partial response to 6-mercaptopurine therapy was noted in 47% of patients, and therapy failed in 53%. The age of the patients, prior resection, or initial symptoms did not influence the response. The clinical response was better in male than in female patients and in patients with involvement of both the small intestine and the colon than in those with only enteritis. 6-Mercaptopurine is a possible alternative to long-term corticosteroid therapy or surgical treatment in selected patients with severe Crohn's disease.
19例重度克罗恩病患者(12例儿童和7例成人)均依赖皮质类固醇治疗,接受了6-巯基嘌呤治疗。所有患者均接受每日50毫克的6-巯基嘌呤剂量;2例儿科患者在2个月后反应不佳,剂量增加至75毫克/天。47%的患者对6-巯基嘌呤治疗有完全或部分反应,53%的治疗失败。患者的年龄、既往切除术或初始症状均不影响反应。男性患者的临床反应优于女性患者,小肠和结肠均受累的患者的临床反应优于仅患有肠炎的患者。对于部分重度克罗恩病患者,6-巯基嘌呤可能是长期皮质类固醇治疗或手术治疗的替代方案。